Mast Cell Activation Syndrome: The Hidden Trigger
Quick Answer
Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells inappropriately release chemical mediators — including histamine, prostaglandins, and cytokines — that may drive chronic multisystem symptoms such as fatigue, brain fog, digestive issues, skin reactions, and anxiety. Standard allergy and inflammation tests often appear normal, making MCAS a frequently overlooked contributor to unexplained, treatment-resistant symptom patterns.
At a Glance
- MCAS involves dysregulated mast cell degranulation releasing histamine, tryptase, prostaglandins, and cytokines into multiple tissue types simultaneously.
- Serum tryptase and plasma histamine levels may fluctuate rapidly, often normalising between symptom flares and yielding false-negative results on standard testing.
- Genetic variants in MTHFR, COMT, and DAO genes may impair histamine metabolism and methylation-dependent detoxification pathways.
- Mast cell activation has been observed in association with Long COVID, postural orthostatic tachycardia syndrome (POTS), and Ehlers-Danlos syndrome (EDS).
- A 2021 global consensus paper by Afrin, Weinstock, and Molderings proposed standardised diagnostic criteria requiring evidence of mast cell mediator elevation plus multisystem symptom involvement.
Mast Cells Are Connective-Tissue Immune Sentinels That May Become Dysregulated
Mast cells are specialised innate immune cells derived from CD34+ haematopoietic progenitors and found throughout connective tissue, including the skin, lungs, gastrointestinal tract, and perivascular spaces. In healthy immune function, mast cells act as first responders, releasing mediators such as histamine, heparin, and tumour necrosis factor alpha (TNF-alpha) to coordinate protective inflammatory responses. In MCAS, these cells may become hyper-responsive, releasing mediators too frequently, in excessive amounts, or in response to non-threatening stimuli — a pattern described by researchers including Lawrence Afrin and Theoharis Theoharides as aberrant mast cell activation.
Multisystem Symptoms Arise Because Mast Cells Are Present in Nearly Every Tissue
Because mast cells reside in nearly every organ system, mast cell activation can produce simultaneous symptoms across multiple body systems, complicating diagnosis.
| Body System | Commonly Reported Symptoms | Key Mediators Involved |
|---|---|---|
| Neurological and Cognitive | Fatigue, brain fog, headaches, dizziness, sleep disturbance | Histamine, interleukins, TNF-alpha |
| Gastrointestinal | Bloating, diarrhoea, nausea, food sensitivities | Histamine, prostaglandin D2, serotonin |
| Skin and Respiratory | Flushing, itching, hives, unexplained rashes, nasal congestion | Histamine, leukotrienes, heparin |
| Cardiovascular and Autonomic | Palpitations, light-headedness, low blood pressure | Histamine, prostaglandins, platelet-activating factor |
| Psychological | Anxiety, irritability, mood instability | Histamine, corticotropin-releasing hormone |
Four Factors Explain Why Conventional Medicine Often Misses MCAS
1. No Single Definitive Diagnostic Test Exists
Biomarkers such as serum tryptase, plasma histamine, urinary N-methylhistamine, and prostaglandin D2 metabolites fluctuate rapidly and may appear within reference ranges between symptom flares. The 2021 global consensus criteria proposed by Afrin, Molderings, and colleagues require documented elevation of at least one mast cell mediator during or shortly after a symptomatic episode.
2. Symptom Overlap with Multiple Established Conditions
MCAS may coexist with or mimic conditions such as irritable bowel syndrome (IBS), eczema, asthma, postural orthostatic tachycardia syndrome (POTS), chronic fatigue syndromes, Ehlers-Danlos syndrome (EDS), and anxiety disorders. Afrin and colleagues have described the POTS-EDS-MCAS triad as a frequently co-occurring clinical presentation.
3. Single-System Diagnostic Models Miss Cross-System Patterns
Conventional care typically evaluates organs in isolation through specialist referral pathways. Mast cells, however, act as cross-system communicators, and their mediators affect neurological, immunological, and gastrointestinal function simultaneously.
4. Emerging Evidence Links MCAS to Post-Viral Inflammatory States
Mast cell activation has been observed in association with Long COVID and other post-viral inflammatory syndromes, where persistent immune activation overlaps with mechanisms commonly seen in post-viral fatigue presentations. Research by Theoharides and colleagues has suggested that SARS-CoV-2 spike protein may directly activate mast cells via toll-like receptor pathways.
Histamine and Inflammatory Cytokines May Affect Brain, Gut, Skin, and Hormonal Function
Brain and Nervous System
Histamine acts as a neurotransmitter in the central nervous system, and elevated levels may disrupt the hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system regulation. Theoharides’ research on neuroinflammation has demonstrated that mast cell-derived mediators can increase blood-brain barrier permeability, potentially contributing to headaches, dizziness, anxiety, and cognitive dysfunction.
Digestive System
Within the gut, mast cells regulate motility, secretion, and intestinal permeability through mediators including histamine and prostaglandin D2. Weinstock and colleagues reported that mast cell activation in the gastrointestinal mucosa may disrupt epithelial tight junctions. These patterns frequently overlap with underlying gut microbiome imbalances and immune-gut signalling disturbances.
Skin and Respiratory System
Cutaneous flushing, urticaria (hives), or pruritus may occur without identifiable IgE-mediated allergens, driven by direct mast cell degranulation in dermal and mucosal tissue.
Hormonal and Immune Interactions
Histamine interacts bidirectionally with oestrogen metabolism — oestrogen can stimulate mast cell degranulation, while histamine may influence oestrogen receptor activity. Some individuals notice symptom flares correlating with menstrual cycles, perimenopause, or hormonal contraceptive changes.
Multiple Root Causes May Drive Mast Cell Hyperreactivity
| Contributing Factor | Proposed Mechanism |
|---|---|
| Chronic or post-infectious immune activation | Persistent antigen exposure may prime mast cells for heightened reactivity |
| Gut dysbiosis | Altered microbiome composition may increase intestinal mast cell density and activation |
| Environmental exposures (e.g., mould, mycotoxins) | Mycotoxins may directly activate mast cells via innate immune receptor pathways |
| High dietary histamine load | Exogenous histamine from fermented foods, aged cheeses, and alcohol may exceed DAO enzyme clearance capacity |
| Nutrient insufficiencies (vitamin C, B6, zinc, copper) | Cofactors required for DAO and HNMT enzyme activity may be depleted |
| Hormonal transitions | Oestrogen fluctuations can modulate mast cell surface receptor expression |
| Chronic psychological stress | Corticotropin-releasing hormone (CRH) may activate mast cells via CRH receptors |
MTHFR, COMT, and DAO Gene Variants May Impair Histamine Clearance
Genetic polymorphisms in methylenetetrahydrofolate reductase (MTHFR), catechol-O-methyltransferase (COMT), or diamine oxidase (DAO) genes may reduce histamine degradation efficiency. MTHFR variants can impair folate metabolism and downstream methylation pathways, potentially affecting the activity of histamine N-methyltransferase (HNMT), one of two primary histamine-degrading enzymes. DAO gene variants, as described by Maintz and Novak (2007), may reduce intestinal histamine breakdown capacity, contributing to histamine intolerance symptoms that overlap with MCAS.
Personalised Functional Assessment May Identify Underlying Contributors
For individuals with persistent, unexplained multisystem symptoms, mast cell activation may provide a unifying explanatory framework. A comprehensive functional medicine assessment may include evaluation of mast cell mediator levels, gut microbiome composition, methylation and detoxification pathway function, nutrient status, and hormonal balance.
Next Steps
- Track your symptoms systematically: Note patterns across multiple body systems, including triggers such as specific foods, environmental exposures, psychological stress, heat, exercise, or hormonal cycles.
- Investigate root contributors: Consider functional testing to assess mast cell mediators (tryptase, histamine, prostaglandin D2 metabolites), gut health, methylation status, and nutrient levels.
- Seek personalised guidance: Work with a practitioner experienced in mast cell activation to develop a targeted, evidence-informed management plan.
Frequently Asked Questions
Key Insights
- MCAS involves excessive release of mast cell mediators including histamine, tryptase, and prostaglandins, causing multisystem symptoms
- Standard allergy and inflammation tests may appear normal between flares due to rapid mediator degradation
- Mast cell activation has been linked to Long COVID, POTS, and Ehlers-Danlos syndrome in emerging research
- Genetic variants in MTHFR, COMT, and DAO may impair histamine clearance and methylation efficiency
- A personalised, cross-system functional medicine approach is essential for accurate assessment and management
Citable Takeaways
- The 2021 global consensus criteria (Afrin et al., Diagnosis journal) proposed that MCAS diagnosis requires documented elevation of at least one mast cell mediator alongside multisystem symptom involvement and response to mast cell-directed therapy.
- Mast cells reside in virtually every vascularised tissue and release over 200 identified mediators, which may explain why MCAS can produce simultaneous symptoms across neurological, gastrointestinal, dermatological, and cardiovascular systems (Theoharides et al., 2012).
- Diamine oxidase (DAO) is the primary enzyme responsible for extracellular histamine degradation in the gut, and genetic DAO polymorphisms may reduce intestinal histamine clearance capacity by up to 50% (Maintz and Novak, American Journal of Clinical Nutrition, 2007).
- The POTS-EDS-MCAS triad has been described as a frequently co-occurring clinical presentation, with Afrin and colleagues reporting significant overlap among these three conditions in clinical practice (Autonomic Neuroscience, 2017).
- Histamine acts as both a peripheral inflammatory mediator and a central neurotransmitter, and Theoharides’ neuroinflammation research suggests mast cell-derived mediators may increase blood-brain barrier permeability (Frontiers in Cellular Neuroscience, 2018).
- Mast cell activation has been observed in post-COVID inflammatory states, with emerging evidence suggesting SARS-CoV-2 spike protein may directly stimulate mast cells through innate immune receptor pathways.
Could Mast Cell Activation Be Behind Your Unexplained Symptoms?
If you experience chronic, multisystem symptoms that conventional testing has not explained, a functional medicine assessment may help identify underlying immune contributors. At Elemental Health and Nutrition, we take a personalised, whole-body approach to complex presentations like MCAS.
References
- Akin C. Mast cell activation disorders. J Allergy Clin Immunol. 2017;139(6S):S47-S54.
- Valent P et al. Mast cell activation syndromes: definition and classification. Allergy. 2012;67(6):694-701.
- Afrin LB et al. Diagnosis of mast cell activation syndrome: a global consensus-2. Diagnosis. 2021;8(2):137-152.
- Theoharides TC et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21-33.
- Weinstock LB et al. Mast cell activation syndrome and the gastrointestinal tract. Gastroenterol Hepatol. 2021;17(3):118-125.
- Butterfield JH. Survey of mediator levels in mast cell activation syndrome. J Allergy Clin Immunol Pract. 2020;8(5):1731-1733.
- Theoharides TC. Mast cells and neuroinflammation. Front Cell Neurosci. 2018;12:478.
- Afrin LB et al. POTS, EDS, and MCAS: the trifecta of common co-morbidities. Auton Neurosci. 2017;203:1-7.
- Galli SJ et al. Mast cells in the development of adaptive immune responses. Nature. 2008;455(7210):41-9.
- Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185-96.
- Comas-Baste O et al. Histamine intolerance: the current state of the art. Biomolecules. 2020;10(8):1181.
- Liu T et al. Quercetin and mast cell stabilisation. Inflamm Res. 2018;67(9):667-678.
- Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211.
- Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2019;74(4):659-668.
